As of 4:04pm ET
| -0.69 / -12.61%|
The 2 analysts offering 12-month price forecasts for Proteostasis Therapeutics Inc have a median target of 9.50, with a high estimate of 13.00 and a low estimate of 6.00. The median estimate represents a +98.74% increase from the last price of 4.78.
The current consensus among 3 polled investment analysts is to Buy stock in Proteostasis Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.